221 related articles for article (PubMed ID: 35622323)
1. cfDNA-Based NGS IG Analysis in Lymphoma.
Pott C; Kotrova M; Darzentas N; Brüggemann M; Khouja M;
Methods Mol Biol; 2022; 2453():101-117. PubMed ID: 35622323
[TBL] [Abstract][Full Text] [Related]
2. Methods for Measuring ctDNA in Lymphomas.
Rossi D; Condoluci A; Spina V; Gaidano G
Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
[TBL] [Abstract][Full Text] [Related]
3. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
Cirillo M; Craig AFM; Borchmann S; Kurtz DM
Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
[TBL] [Abstract][Full Text] [Related]
5. Next-Generation Sequencing-Based Clonality Detection of Immunoglobulin Gene Rearrangements in B-Cell Lymphoma.
van Bladel DAG; van der Last-Kempkes JLM; Scheijen B; Groenen PJTA;
Methods Mol Biol; 2022; 2453():7-42. PubMed ID: 35622318
[TBL] [Abstract][Full Text] [Related]
6. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
Brüggemann M; Kotrová M; Knecht H; Bartram J; Boudjogrha M; Bystry V; Fazio G; Froňková E; Giraud M; Grioni A; Hancock J; Herrmann D; Jiménez C; Krejci A; Moppett J; Reigl T; Salson M; Scheijen B; Schwarz M; Songia S; Svaton M; van Dongen JJM; Villarese P; Wakeman S; Wright G; Cazzaniga G; Davi F; García-Sanz R; Gonzalez D; Groenen PJTA; Hummel M; Macintyre EA; Stamatopoulos K; Pott C; Trka J; Darzentas N; Langerak AW;
Leukemia; 2019 Sep; 33(9):2241-2253. PubMed ID: 31243313
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
8. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
[TBL] [Abstract][Full Text] [Related]
9. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
[TBL] [Abstract][Full Text] [Related]
10. Cell-free DNA in large B-cell lymphoma: MRD and beyond.
Sworder BJ; Kurtz DM
Semin Hematol; 2023 Jul; 60(3):142-149. PubMed ID: 37474409
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
Kwok M; Wu SP; Mo C; Summers T; Roschewski M
Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
[TBL] [Abstract][Full Text] [Related]
12. Ultrasensitive Detection of Circulating Tumor DNA in Lymphoma via Targeted Hybridization Capture and Deep Sequencing of Barcoded Libraries.
Alcaide M; Rushton C; Morin RD
Methods Mol Biol; 2019; 1956():383-435. PubMed ID: 30779047
[TBL] [Abstract][Full Text] [Related]
13. Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.
Garg S; Kumar A; Gupta R
Clin Transl Oncol; 2021 Nov; 23(11):2206-2219. PubMed ID: 33991328
[TBL] [Abstract][Full Text] [Related]
14. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
Fici P
Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
[TBL] [Abstract][Full Text] [Related]
15. Validation of a next-generation sequencing assay for the detection of EGFR mutations in cell-free circulating tumor DNA.
Stitz R; Buder A; Silye R; Baumgartner B; Pühringer F; Filipits M; Oberndorfer E; Heitzer E
Exp Mol Pathol; 2021 Dec; 123():104685. PubMed ID: 34560086
[TBL] [Abstract][Full Text] [Related]
16. Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas.
Meriranta L; Pitkänen E; Leppä S
Semin Hematol; 2023 Jul; 60(3):132-141. PubMed ID: 37455222
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS.
Scheijen B; Meijers RWJ; Rijntjes J; van der Klift MY; Möbs M; Steinhilber J; Reigl T; van den Brand M; Kotrová M; Ritter JM; Catherwood MA; Stamatopoulos K; Brüggemann M; Davi F; Darzentas N; Pott C; Fend F; Hummel M; Langerak AW; Groenen PJTA;
Leukemia; 2019 Sep; 33(9):2227-2240. PubMed ID: 31197258
[TBL] [Abstract][Full Text] [Related]
18. ClonoSEQ assay for the detection of lymphoid malignancies.
Monter A; Nomdedéu JF
Expert Rev Mol Diagn; 2019 Jul; 19(7):571-578. PubMed ID: 31179776
[No Abstract] [Full Text] [Related]
19. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
20. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
